Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

198.80 +1.52 (+0.77%)
Streaming Delayed Price Updated: 10:26 AM EDT, Sep 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
2 S&P 500 Stocks to Consider Right Now and 1 We Question
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec... 
Via StockStory
Topics Stocks
News headline image
Moderna vs. BioNTech: Which mRNA Cancer Stock Has More Upside? ↗
Moderna has the clinical lead, while BioNTech has the deeper war chest. See which cancer stock offers the stronger long-term setup as mRNA oncology enters a new phase. 
Via The Motley Fool
News headline image
Up Over 550% in 2026, Is It Too Late to Buy Moderna Stock? ↗
Positive news surrounding its personalized cancer vaccine has lit a fire under the healthcare stock. 
Via The Motley Fool
These S&P500 stocks that are showing activity before the opening bell on Monday. ↗
Via Chartmill
Discover which S&P500 stocks are making waves on Thursday. ↗
Via Chartmill
News headline image
Moderna Eyes Cancer Vaccine Filing as It Expands Beyond COVID ↗
Moderna (NASDAQ:MRNA) executives emphasized the company’s evolution beyond COVID-19 vaccines during a discussion with Bernstein, highlighting its mRNA platform, personalized cancer vaccine program... 
Via MarketBeat
News headline image
Which Is the Bigger Story for BioNTech -- Its Colorectal Cancer Vaccine Setback or the Lung Cancer Clinical Success? ↗
The company is looking to prove it can achieve significant success outside the coronavirus market. 
Via The Motley Fool
News headline image
Is Moderna Stock a Buy After Its Melanoma Breakthrough? ↗
Moderna's story is changing fast, but the stock is already pricing in a lot. See what the Phase 3 cancer result really proves, what could come next, and where the biggest risk still sits. 
Via The Motley Fool
Discover which S&P500 stocks are making waves on Tuesday. ↗
Via Chartmill
These S&P500 stocks are moving in today's session ↗
Via Chartmill
News headline image
Should You Buy Moderna Stock? Why Many Wall Street Analysts Say "No." ↗
Following last month's super rally, a growing number of analysts are now calling for caution. 
Via The Motley Fool
Discover the top S&P500 movers in Tuesday's pre-market session. ↗
Via Chartmill
Meta's Muse Sends the Nasdaq to a Record and Rekindles the AI Trade ↗
Via Chartmill
Topics Artificial Intelligence
News headline image
BioNTech Stock Recently Got Downgraded. But Is Wall Street Underestimating Its Cancer Pipeline? ↗
Investors buying this biotech stock now will get its pipeline essentially for free. 
Via The Motley Fool
Monday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
News headline image
Moderna (MRNA) Stock Trades Up, Here Is Why
What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 9.4% in the afternoon session after positive Phase 3 INTerpath-001 trial results ... 
Via StockStory
Topics Artificial Intelligence
Discover which S&P500 stocks are making waves on Monday. ↗
Via Chartmill
News headline image
Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026
Phase 3 data for intismeran autogene in the adjuvant treatment of patients with resected stage IIB-IV melanoma selected for presentation at a Presidential Symposium Moderna to host an investor event... 
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Axsome Therapeutics vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026? ↗
One company is growing a commercial drug business with limited margin for error on the path to profitability. The other has a platform that proved itself at global scale and keeps finding new diseases... 
Via The Motley Fool
News headline image
BioNTech Threw in the Towel on Its Colorectal Cancer Vaccine Trial. Should Investors Be Worried? ↗
BioNTech's recent pipeline setback is a real cause of concern. But investors shouldn't panic. 
Via The Motley Fool
What's going on in today's session: S&P500 movers ↗
Via Chartmill
News headline image
Why Are Moderna (MRNA) Shares Soaring Today
What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 7.1% in the afternoon session after the company presented at the Morgan Stanley G... 
Via StockStory
Topics Artificial Intelligence
Which S&P500 stocks are moving on Thursday? ↗
Via Chartmill
Thursday's pre-market session: top gainers and losers in the S&P500 index ↗
Via Chartmill
News headline image
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
EQNX::TICKER_START (NYSE:NNVC),(NASDAQ:GILD),(NASDAQ:MRNA),(NYSE:PFE),(NASDAQ:BNTX) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
A Growing Global Threat From Emerging Viruses Is Fueling Urgent Demand For New Treatments And Creating A Potentially Massive Market For Innovative Antiviral Developers 
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Unpopular Stocks Walking a Fine Line
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord... 
Via StockStory
News headline image
Moderna's COVID Vaccine Was a Historic Success. Could Its Cancer Vaccine Be Even Bigger? ↗
The biotech is entering a new era. 
Via The Motley Fool
News headline image
Moderna’s Cancer Vaccine Win Fuels Broad Push Across Tumor Types ↗
Moderna (NASDAQ:MRNA) President Stephen Hoge said the company’s recently announced positive Phase III results for its investigational personalized cancer vaccine, intismeran, in adjuvant melanoma... 
Via MarketBeat
News headline image
Blue-Chip Stocks Are Looking Anything But Boring With Dividends and Big 2026 Gains ↗
Coca-Cola, Chevron, and Merck have outperformed the S&P 500 in 2026, each pairing strong share-price gains with growing dividends backed by solid fundamentals. 
Via MarketBeat
Topics Artificial Intelligence Intellectual Property Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.